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Abstract. Long-term glucocorticoid therapy has improved outcomes in patients with Duchenne muscular dystrophy. However,
the recommended glucocorticoid dosage suppresses the hypothalamic-pituitary-adrenal axis, leading to adrenal insufficiency
that may develop during severe illness, trauma or surgery, and after discontinuation of glucocorticoid therapy. The purpose of
this review is to highlight the risk of adrenal insufficiency in this patient population, and provide practical recommendations
for management of adrenal insufficiency, glucocorticoid withdrawal, and adrenal function testing. Strategies to increase
awareness among patients, families, and health care providers are also discussed.
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INTRODUCTION
Duchenne muscular dystrophy (DMD) is an
X-linked recessive neuromuscular disease, character-
ized by progressive muscle weakness, with eventual
loss of ambulation and premature death [1]. Incidence
of DMD has been reported as one case per 3500–5000
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male newborns [2–5]. Therapy with glucocorticoids
(GC) improves muscle strength, prolongs ambula-
tion and maintains cardiac muscle and pulmonary
function [6, 7]. Nevertheless, prolonged use of
daily GC therapy is associated with significant side
effects including cushingoid features, obesity, abnor-
mal glucose tolerance, growth retardation, delayed
puberty, hypertension, adverse behavioral changes
and increased fracture risk [8–10]. Often over-
looked, however, is the iatrogenic suppression of
the hypothalamic-pituitary-adrenal (HPA) axis, i.e.
adrenal suppression, with resultant secondary adrenal
insufficiency (AI).
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Secondary AI is different from primary AI or
Addison disease in that the primary AI is caused
by destruction or dysfunction of the adrenal gland
(primary adrenal gland disorder), whereas, secondary
AI is due to deficient pituitary adrenocorticotrophic
hormone (ACTH) secretion, or suppressed ACTH
secretion secondary to chronic GC therapy. Acute
AI or adrenal crisis is a life-threatening condition
that may develop during physiological stress events
when patients decompensate and are not able to meet
the increased demand of cortisol. AI secondary to
chronic GC therapy may persist long after exoge-
nous GC therapy is discontinued. AI in boys and
men with DMD may occur in several scenarios,
including abrupt cessation of GC, during gastroin-
testinal infection or febrile illness with emesis that
inhibits normal absorption of GC, or when patients
undergo surgery and do not receive GC stress dose
coverage peri-operatively. The prevalence of symp-
tomatic AI or adrenal crisis in patients with DMD is
unknown as routine screening is generally not per-
formed and no studies have systematically addressed
this issue. Evidence suggests that morbidity and
mortality associated with acute AI or adrenal crisis
are still high among individuals with AI from var-
ious disorders [11, 12]. Some unexplained deaths
among patients with DMD during acute illnesses
have been speculated to be related to adrenal cri-
sis rather than cardiac complications or other acute
stressor/illness. One young man with DMD died
following an orthopedic surgery for humerus and
femur fractures when he developed hypotension
postoperatively without the benefit of GC supple-
mentation [13]. This patient had been on chronic
daily GC for many years, thus, this medically sig-
nificant stress event occurred during a time that
adrenal function was likely suppressed. It was deter-
mined only after a careful retrospective chart review
that he likely suffered from adrenal crisis, because
he had not received consistent GC replacement
during his hospitalization [13]. This led to the Par-
ent Project Muscular Dystrophy’s development and
publication of the “PJ Nicholoff Steroid Protocol”
(www.ParentProjectMD.org/PJ). This young man’s
story serves as an important reminder of the real risk
of AI in people living with DMD who are taking daily
GC. This story also highlights the need to increase
awareness of adrenal suppression among health care
providers and the need for GC management during
stress events in patients with DMD.
The purpose of this review is to provide physicians
and other health care professionals caring for patients
with DMD an overview of the physiology of the HPA
axis, the pharmacology of GC, management of AI
and acute adrenal crisis, and practical recommenda-
tions for GC withdrawal and adrenal function testing.
Strategies to increase awareness among patients, fam-
ilies, and health care providers are also discussed.
Noting that research on AI in patients with DMD
is lacking, it is our hope that this review will serve
as a framework for future research and to facil-
itate AI surveillance/monitoring, with the goal of
improving recognition and preventing complications.
Additional work is needed to better understand the
true epidemiology of AI in patients with DMD on
long-term GC therapy.
The physiology of the HPA Axis
The HPA axis is a central stress response sys-
tem that stimulates production and release of cortisol
from the adrenal gland. Cortisol acts to support vas-
cular tone, increases availability of glucose, and
maintains intravascular volume. When the body
encounters a stressor (e.g., surgery, trauma), the
hypothalamus is activated and releases corticotropin-
releasing hormone (CRH), which acts on the anterior
pituitary gland to stimulate release of adrenocor-
ticotropin hormone (ACTH). ACTH then activates
the adrenal gland to release cortisol. The HPA
axis has a negative feedback mechanism, such that
increased circulating cortisol levels inhibit both the
hypothalamus and pituitary glands to suppress release
of CRH and ACTH (Fig. 1). Conversely, insuffi-
cient cortisol stimulates increased release of CRH
and ACTH.
Normal basal secretion of cortisol from the adrenal
gland in unstressed individuals is 5–7 mg/m2/day
for adolescents [14] or 8–10 mg/day for adults [15].
This basal secretion is equivalent to approximately
10–12 mg/m2/day of hydrocortisone administered
orally to compensate for the incomplete bioavail-
ability secondary to intestinal absorption and hepatic
metabolism [11]. The basal secretion increases
3–5 times during minor illnesses or surgery to
approximately 30–50 mg/m2/day [16]. These small
increases during uncomplicated minor surgery return
to baseline in 24 hours. Procedures producing
greater surgical stress (e.g., a spinal surgery)
have been shown to increase cortisol responses to
75–150 mg/day or 10x normal physiologic secre-
tion, and can reach between 200 and 500 mg/day in
emergent surgery or severe trauma [17, 18]. In most
instances, basal cortisol secretion returns to base-
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Fig. 1. Regulation through cortisol-mediated negative feed-
back of the hypothalamic-pituitary-adrenal (HPA) axis;
CRH = corticotropin-releasing hormone, ACTH = adrenocorti-
cotropin hormone. Figure designed with images from Servier
Medical Art (https://smart.servier.com) under a Creative
Commons Attribution 3.0 Unported License.
line about 5 days post operatively from these more
complex surgeries [18].
The recommended daily dosage of GC
suppresses the HPA axis in DMD
Different types of synthetic GC preparations exert
different pharmacologic effects based on their gluco-
corticoid, mineralocorticoid and anti-inflammatory
activity. To determine the likelihood of adrenal sup-
pression, one needs to consider the GC potency.
Potency of different types of GC is measured using
hydrocortisone as a reference, with potency value
of 1. Daily prednisone and deflazacort are pre-
scribed for patients with DMD at 0.75 mg/kg/day and
0.9 mg/kg/day, respectively [19]. Prednisone has a
relative potency of 4 when compared to hydrocorti-
sone [20]. Therefore, if a boy with DMD who weighs
30 kg (body surface area of 1 m2) takes 22 mg pred-
nisone a day, the equivalent dose of hydrocortisone
is 88 mg (22 × 4). This is approximately 8 times the
physiologic dose of hydrocortisone (10 mg/m2/day).
Prednisone 1 mg is equivalent in anti-inflammatory
effect to 1.2 mg deflazacort [21]. Thus, for patients
with DMD, the long term use of either daily pred-
nisone or deflazacort at these recommended dosages
that clearly exceed the physiologic dose of hydrocor-
tisone would likely suppress the HPA axis, resulting
in secondary AI [22].
Adrenal insufficiency after long-term
glucocorticoid therapy
The Pediatric Endocrine Society recommends that
adrenal suppression be considered in all children who
have received supraphysiologic doses of oral daily
GC (>12 mg/m2/day hydrocortisone or equivalent)
for two weeks or longer [11]. Long duration phar-
macologic administration of synthetic GC, through
negative feedback on the hypothalamus/pituitary
(Fig. 1), leads to suppression of the HPA axis, with
reduced production of CRH and ACTH, resulting
in secondary AI [22]. Suppression of the HPA axis
causes decreased stimulation of the adrenal cortex
and progressive partial or total atrophy of the adrenal
glands, with decreased or absent adrenal reserve [22].
There is a great deal of individual variability in
susceptibility to suppression of the HPA axis after
withdrawal of chronic daily GC therapy [23, 24]. As
a result, it is not possible to predict with confidence
which patients will develop AI. Clinical variables
including age, type and dosing regimen of GC, dura-
tion of treatment, cumulative GC dose, or time since
GC withdrawal and basal cortisol levels are not pre-
dictive for AI assessed by peak cortisol on low-dose
ACTH stimulation test [23–25]. In a recent study
in Canada, adrenal crisis occurred in 13% of chil-
dren with symptomatic adrenal suppression [26]. AI
and/or adrenal crisis may result in significant mor-
bidity and mortality, prolonged hospitalization and
intensive care unit admission [27].
Risk of adrenal crisis and adrenal insufficiency in
DMD
Patients treated with chronic GC who display
cushingoid features should be assumed to have
steroid-induced adrenal suppression [28, 29]. These
patients show no signs of AI while on daily GC dur-
ing the unstressed state, but may decompensate and
develop acute AI when encountering physiological
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stress such as infection, surgery, or trauma, due to
inability to produce sufficient additional cortisol to
meet the stress demand. Common major surgery that
would require GC stress dosing in DMD includes
spinal surgery for scoliosis, tendon surgery for mus-
culotendinous contractures, or open reduction for
fractures of long bones. Surgery for scoliosis has
become less frequent after the use of GC therapy in
DMD [30]; recent study indicates that 20% of GC-
treated group and 92% in the non GC-treated group
developed scoliosis and underwent spinal surgery
[31]. Prolonged treatment with GC results in osteo-
porosis, which increases the risk of low-trauma long
bone fractures in patient with DMD. Recent studies
indicate that 43% of patients living with DMD expe-
rience one or more fractures [32]. Both the experience
of the fracture, as well as the possible need for sur-
gical management, result in additional physiologic
stress.
Patients with DMD may develop AI in these clin-
ical circumstances:
1. AI can occur after abrupt withdrawal of GC after
long-term therapy, whether voluntary cessation
of therapy by patients, or if GC is inadvertently
not given (i.e. hospitalization without contin-
uation of GC), or due to illness that inhibits
absorption of GC (e.g. gastroenteritis). Patients
and caregivers must be educated about this risk
and avoid discontinuing GC therapy without
the physician guidance. Gradual tapering of GC
doses allows the HPA axis to recover and also
prevents steroid withdrawal or deprivation syn-
drome [33].
2. AI can also occur in patients encountering
severe physiological stress events while on a
GC dose that is inadequate to provide GC cov-
erage for stress. For example, a patient weighing
30 kg (with body surface of 1.0 m2) taking
15 mg of prednisone daily is on a dose that
is above physiologic requirements and, there-
fore, would suppress the HPA axis. This patient
would not experience AI symptoms as long
as he takes prednisone daily. When he expe-
riences mild to moderate stress, the prednisone
dose, which is equivalent to 60 mg hydrocor-
tisone, is sufficient to provide moderate stress
coverage. In the event of significant trauma
or major surgery, this daily prednisone dose
(or 60 mg hydrocortisone) is insufficient to
cover major stress, which would require 100 mg
hydrocortisone. Therefore, the patient would
need additional GC to provide major stress
coverage.
Signs and symptoms of AI and adrenal crisis
In patients with adrenal suppression, severe phys-
iological stress can precipitate adrenal crisis, a
life-threatening condition with ultimate signs of
postural hypotension, dehydration, shock or coma.
Clinicians must have high index of suspicion of AI in
these patients, since early signs and symptoms of AI
such as fatigue, nausea, vomiting, dizziness, or postu-
ral hypotension are non-specific and can be mistaken
for symptoms of concurrent illness (such as viral
gastroenteritis). Electrolyte abnormalities including
hyponatremia and hypoglycemia can develop. Unlike
primary AI (where hyperkalemia is common due to
deficient aldosterone secretion), hyperkalemia is not
observed in secondary AI [11].
MANAGEMENT
Acute management of AI and adrenal crisis
When encountering DMD patients with acute
AI, immediate treatment with stress dose par-
enteral hydrocortisone, 100–150 mg or 100 mg/m2
intravenously or intramuscularly, and saline bolus
(10 ml/kg) is indicated. This is followed by intra-
venous hydrocortisone at stress dose (Fig. 2) given
as continuous infusion over 24 hours or intravenous
boluses divided into 4 doses (every 6 hours), along
with intravenous isotonic saline with dextrose infu-
sion to restore intravascular volume, and normalize
serum sodium and glucose concentrations. Recogni-
tion and treatment of stress-precipitating conditions
such as infection or trauma is also undertaken simul-
taneously. The stress hydrocortisone dose can be
tapered over 2–3 days, if clinically appropriate, back
to the home GC regimen for patients who are on
chronic daily GC therapy. For patients who have
abruptly discontinued long-term GC therapy, the
stress hydrocortisone dose should be tapered to a
physiologic hydrocortisone replacement therapy of
10–12.5 mg/m2/day, and continued for a period of at
least 1–2 months until further assessment of HPA axis
is performed to ensure recovery of adrenal function.
Physiologic replacement therapy, plus “stress doses”
during physiological stress may need to be continued
for a long period, as recovery of HPA suppression
may take as long as 12–20 months [34].
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Fig. 2. Recommendations for steroids stress dose coverage for different degrees of stress [45].
Stress replacement during stressful events
(illness, injury or surgery)
Cortisol secretion increases proportionate to the
degree of stress [17]. A daily therapeutic dose of
prednisone or deflazacort in boys with DMD gener-
ally provides sufficient coverage for mild to moderate
stress, provided that the patient is able to take oral GC.
However, this therapeutic dose is usually not suffi-
cient for major stress (surgery, septic shock, multiple
fractures), and the patients would require supplemen-
tal GC stress dosing (Fig. 2). The stress doses of GC
can be rapidly reduced back to the therapeutic dose
once clinically improved. If an illness causes patients
to be unable to take oral medications, hydrocortisone
must be administered parenterally at 25 mg/m2/dose
q 6 hours.
Some clinicians use intermittent GC regimens
including twice weekly, or first 10 days of the month,
or 10 days on and 10 days off. Twice weekly GC
have not been associated with either growth arrest
or cushingoid features [35]. While boys and men on
these dosing regimens may be at lower risk of adrenal
suppression or AI, this has not been formally stud-
ied. Therefore, the recommendations contained here
should be considered.
Recommendation for withdrawal of long-term
glucocorticoid therapy
Although long-term GC therapy is recommended
in patients with DMD even after loss of ambu-
lation to preserve cardiac and pulmonary function
[7, 36, 37], some patients and/or medical providers
still opt for discontinuation of therapy. There are no
evidence-based guidelines on how to best taper GC
after long-term daily therapy. A systematic review on
GC withdrawal in chronic medical disorders found
insufficient evidence of the efficacy and safety of
the different withdrawal regimens [38]. Thus, recom-
mendations for withdrawal of long-term GC therapy
are based on expert opinion. There is a substan-
tial individual variation in recovery rate of adrenal
suppression. Clinicians need to monitor the patients
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Table 1
Prednisone or deflazacort tapering regimen
Patients on daily prednisone or deflazacort:
Step 1: Taper from pharmacologic to physiologic doses
1.1) Start on a Monday, reduce corticosteroids by 20–25% for 2 weeks (or longer).
1.2) Taper by 20–25% again every 2 weeks (or longer), until dose is near physiologic dose (3 mg/m2/day or 0.1 mg/kg/day of
prednisone or 3.6 mg/m2/day 0.12 mg/kg/day of deflazacort).
1.3) When near physiologic dose, switch prednisone or deflazacort to hydrocortisone at 12 mg/m2/day, given twice a day, with higher
dose (about 2/3 of total daily dose) in the morning. Provide extra supply of hydrocortisone to be used for stress doses if needed in
times of stress events.
1.4) Educate patients and caregivers on adrenal insufficiency and corticosteroid stress dosing.
1.5) Endocrinology outpatient consultation is highly recommended for patient education and evaluation of recovery of HPA axis.
Step 2: Taper from physiologic dose to complete withdrawal of corticosteroids
2.1) Continue to taper off hydrocortisone by 20–25% each week (or every 2 weeks).
2.2) If patients have symptoms of adrenal insufficiency during the taper, the previous steroid dose prior to the taper should be
maintained for another week or longer.
2.3) Omit the evening dose when the dose is low. Give morning single dose for 1–2 weeks, then every other day for 2 weeks (or longer).
2.4) Discontinue the hydrocortisone and WATCH VERY CAREFULLY FOR SIGNS OF ADRENAL INSUFFICIENCY/CRISIS
(Table 1).
2.5) If encountering a serious illness or injury during the taper, the patient should receive a “stress dose” of hydrocortisone (Figure 1).
2.6) Encourage parents to continue to report any serious physiological stress events (such as surgery) until 1 year post-taper to
determine whether stress steroid dosing is necessary.
2.7) Educate patients and caregivers that they need to go to the emergency room if patients have signs or symptoms of adrenal crisis.
Serum electrolytes, glucose and cortisol levels should be obtained.
closely and educate both patients and caregivers
about the signs and symptoms of AI and slow the
rate of tapering if needed. Table 1 outlines one rec-
ommendation for tapering chronic daily GC, with 2
important steps: first is to taper from pharmacologic
dose to physiologic dose; second step is to taper from
physiologic dose to discontinuation. When the GC
dose is near or below physiologic, it is critical to mon-
itor for signs or symptoms of adrenal insufficiency,
especially when patients encounter stress events. It
is therefore recommended that during the process of
tapering in step 1, outpatient endocrinology consul-
tation be obtained to establish care, provide teaching
on AI as well as stress dosing, and to plan for adrenal
function testing after the discontinuation of GC. Clin-
icians should have a low threshold to test and treat for
AI, especially when patients develop symptoms sug-
gestive of AI during the tapering and after cessation
of GC. Written information on AI and adrenal sup-
pression with steroid emergency card (Fig. 3) should
also be provided to patients and caregivers.
Assessing recovery of the
hypothalamic-pituitary-adrenal axis
There have been no studies assessing adrenal func-
tion and timing of recovery in patients with DMD
after long-term GC therapy. In a study of children
treated with long-term GC therapy for rheumatic dis-
ease, AI based on inadequate response to low-dose
ACTH stimulation test was found in 32% and 11% at
Fig. 3. Steroid emergency card, front and back. A complete DMD
emergency card that includes all aspect of care for patients with
DMD is available at the Parent Project Muscular Dystrophy web-
site [49].
1 month and 20 months, respectively, after discontin-
uation of GC [34]. A study by Graber et al evaluating
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Table 2
Assessment of hypothalamic-pituitary axis after corticosteroid withdrawal. After reaching half
the physiologic dose (5–6 mg/m2/day of hydrocortisone) or less, obtain morning cortisol
monthly to determine if hydrocortisone can be discontinued
recovery of the HPA axis after withdrawal of chronic
GC therapy demonstrated that ACTH was the first to
normalize (after 2–5 months), followed by morning
serum cortisol (after 6–9 months), and finally corti-
sol after adrenal stimulation testing with ACTH (after
9 months), which is thought to best reflect response to
physiologic stress [39]. Based on this knowledge, it
is recommended that assessment of morning cortisol
be obtained when the tapering process is reaching
half the physiologic dose or less to determine if
hydrocortisone can be discontinued [40], as guided
by morning cortisol values outlined in Table 2. The
HPA axis is intact and daily hydrocortisone is dis-
continued when morning cortisol is > 18g/dL (or
> 500 nmol/L). When morning cortisol is between
7–18g/dL, adrenal function is likely adequate for
non-stressed state, but may be inadequate for stress.
Thus, daily hydrocortisone is discontinued but stress
dosing at time of stress is continued until a low-dose
ACTH stimulation test (protocol shown in Table 3)
is obtained to document recovery of the HPA axis
[41]. Alternatively, clinicians may skip morning cor-
tisol testing and perform ACTH stimulation test 2–3
months after discontinuation of hydrocortisone. In
the absence of evidence-based guidelines, clinicians
may choose to gradually taper off GC therapy without
HPA testing as described above, with great vigi-
lance for signs and symptoms of AI. It is also a
safe approach to consider patients as having adrenal
suppression for up to 1 year after discontinuation
of GC therapy and to provide prophylactic therapy
with hydrocortisone when there is any concern for
AI, especially at time of stress.
Special considerations for non-daily
glucocorticoid therapy in DMD
The dosing and type of corticosteroid use varies
widely within the United States and around the world.
In the United States, besides the daily prednisone and
daily deflazacort regimens, twice weekly only pred-
nisone at 5 mg/kg twice weekly (10 mg/kg/week) has
also been used and has been shown to be equally
effective as daily prednisone in preserving muscle
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Table 3
Protocol for low-dose ACTH stimulation test to assess HPA axis
1. Fasting is not necessary.
2. On arrival obtain height and weight, and vital signs.
3. If patient desires, lidocaine 4% cream (2.5 gram) can be applied to site 20–30 minutes prior to intravenous (IV) insertion.
4. Place saline lock – 0.9% NS 10 mL flush for blood draws and after IV medications.
5. Obtain baseline blood sample for cortisol at (t = 0).
6. Prepare cortrosyn dilution: Dilute 250 mcg into 10 ml normal saline, mix well. Each 0.04 ml (4 units on insulin syringe) contains 1
microgram cortrosyn.
7. Give cortrosyn 1 mcg IV at t = 0 minute. Inject as close as possible to the IV catheter and immediately flush with normal saline to
avoid adherence of cortrosyn to IV tubing.
8. Draw cortisol at t = 20, 40 minutes.
strength over 12-month period [35]. Despite the fact
that linear growth is maintained and cushingoid fea-
tures are not observed, even after years [42], it is
prudent to consider, evaluate, and treat for AI during
stress. While formal adrenal testing has not been per-
formed routinely, ACTH stimulation tests performed
in children prior to surgery have shown normal results
(AMC personal communication).
Efficacy of daily prednisone at 0.75 mg/kg/day
10 days on/10 days off commonly used in Europe
has also been reported [43] and again, linear growth is
preserved and cushingoid features are less common.
Again, there have been no published studies examin-
ing the extent of adrenal suppression during the off
days in the patients on these regimens. It is prudent
to assume that the patients may have adrenal sup-
pression. We recommend that if patients are unable
to take GC by mouth due to nausea, vomiting, or
need to be fasted for a procedure, the patients should
be given stress doses intravenously as indicated in
Fig. 2. When these patients encounter stress events
during the off days, stress dose hydrocortisone may
be given if clinically indicated. If the patients experi-
ence signs and symptoms of AI, or encounter major
stress, serum cortisol level may be drawn prior to
stress dosing, if possible, to document AI (cortisol
level < 18 ug/dL or < 500 nmol/L during stress event
would suggest AI). Future studies to evaluate adrenal
function in patients on intermittent GC regimens are
needed.
Strategies to increase awareness of adrenal
insufficiency and translate guidelines into
practice improvements
Morbidity and mortality associated with AI can be
prevented by increased recognition and awareness of
adrenal suppression and risk of AI and adrenal crisis
among patients, caregivers and health care providers.
Recently a death related to AI in a patient with
DMD has catalyzed the development of a protocol
named “PJ Nicholoff Steroid Protocol” in memory
of the patient [13]. This protocol, developed through
an effort by Parent Project Muscular Dystrophy and
St. Vincent’s Hospital of Indianapolis, is available
on the Parent Project Muscular Dystrophy (Parent-
projectMD.org) and Muscular Dystrophy (MDA.org)
websites [46, 47]. How these recommendations or
guidelines translate into practice and improve out-
come has yet to be studied. A recent prospective study
showed that the incidence of adrenal crisis remained
high due to failure to properly administer GC stress
doses among patients with chronic AI, despite hav-
ing prior education [44]. This study highlights the
need to identify effective strategies to improve edu-
cation among patients and caregivers and to improve
quality of care delivery related to AI by health care
providers. We have designed a quality-improvement
diagram (Fig. 4) that include the aim statement, key
drivers and the interventions to help increase aware-
ness and education on AI and adrenal suppression.
We encourage physicians caring for DMD patients
to adopt this quality-improvement project and make
both the emergency card (Fig. 3) and mobile app
[48] available to patients seen in their practice, as
well as encouraging patients to wear medical ID
alerting first responders to their diagnosis, allergies
and medications (i.e., “daily corticosteroids”). One
important strategy that needs to be emphasized is
to add “Steroid-induced adrenal suppression” to the
“Problem List” in the patient’s medical record, to alert
physicians caring for patients in the urgent care facil-
ity or emergency department for the risk of AI. It is
also important for the muscular dystrophy care team
to provide families with a method to link them with
the neuromuscular team in case of an emergency, and
to re-assess patients’ and caregivers’ understanding
and knowledge on AI risks at each clinic visit.
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Fig. 4. Key drivers for our quality-improvement project. Shown is the learning structure including the aim statement, key drivers, and the
intervention strategies to be implemented to increase awareness of adrenal suppression and risk of adrenal insufficiency or adrenal crisis.
The key drivers are the elements believed to be crucial for achieving the aim.
CONCLUSIONS
Chronic GC therapy causes adrenal suppression in
patients with DMD, therefore, clinicians must have
high index of suspicion for AI and GC stress dosing
should be given to patients at the time of signifi-
cant physiologic stress events. Education regarding
AI risks must be provided to caregivers and patients
with DMD on long-term GC therapy to prevent mor-
bidity and mortality associated with AI or adrenal
crisis.
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